Foghorn Therapeutics Inc.

FHTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $80.9M $55.5M $80.3M $52.2M $101.1M $92.8M $15.0M $40.6M
Accounts Receivable
Inventory
Total Current Assets $163.2M $249.6M $240.2M $351.4M $459.6M $190.7M $16.9M
Property, Plant & Equipment $19.5M $2.7M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $198.1M $284.0M $285.9M $404.9M $519.8M $255.6M $22.3M
Liabilities
Accounts Payable $4.3M $3.8M $6.3M $5.4M $3.8M $3.7M $3.4M
Total Current Liabilities $59.7M $67.0M $58.4M $55.2M $48.7M $18.8M $12.7M
Long-Term Debt $0 $19.7M $11.0M
Total Liabilities $306.6M $329.5M $363.1M $404.8M $422.9M $109.4M $23.8M
Stockholders' Equity
Retained Earnings $-632.5M $-558.2M $-471.6M $-373.1M $-264.3M $-162.9M $-94.1M
Total Stockholders' Equity $-108.5M $-45.5M $-77.2M $112.0K $96.9M $146.2M $-88.0M $-39.3M